

Supplementary Results, National Pancreatic Cancer Audit (NPacA) State of the Nation Report September 2026


Supplementary Figure 1. Percentage of people with stage 4 pancreatic cancer diagnosed in England during 2022-23 who received a form of disease-targeted treatment (surgery, chemotherapy, radiotherapy), by performance status and age 1

Supplementary Figure 2. 1-year survival rate after diagnosis, unadjusted and case-mix adjusted, for people diagnosed with pancreatic cancer between 1 January 2022 and 31 December 2023 in England 2


Supplementary Table 1. Characteristics of people diagnosed with extrahepatic bile duct or ampullary tumours in England (2022-2023) and Wales (2023-2024) 3

Supplementary Table 2. Care of people diagnosed with extrahepatic bile duct or ampullary tumours in England (2022-2023) and Wales (2023-2024) 4

Supplementary Figure 1. Percentage of people with stage 4 pancreatic cancer diagnosed in England during 2022-23 who received a form of disease-targeted treatment (surgery, chemotherapy, radiotherapy), by performance status and age



Supplementary Figure 2. 1-year survival rate after diagnosis, unadjusted and case-mix adjusted, for people diagnosed with pancreatic cancer between 1 January 2022 and 31 December 2023 in England



Supplementary Table 1. Characteristics of people diagnosed with extrahepatic bile duct or ampullary tumours in England (2022-2023) and Wales (2023-2024)

	England	Wales
No. of people	2,534	79
Sex		
Male		65%
Female		35%
Age at diagnosis (years)		
<60	14%	14%
60-69	22%	15%
70-79	35%	42%
≥80	29%	29%
Ethnicity		
White	90%	97%
Asian or Asian British	5%	3%
Black or Black British	2%	<1%
Mixed	1%	<1%
Other ethnic group	2%	<1%
Unknown	n=79	n=42
TNM stage at diagnosis		
1	16%	49%
2	21%	23%
3	33%	11%
4	30%	17%
Unknown	n=814	n=26
Index of Multiple Deprivation quintile		
1 – most deprived	18%	23%
2	19%	16%
3	21%	20%
4	22%	17%
5 – least deprived	21%	24%
Unknown		n=4
Performance status		
0 – fully active	42%	42%
1	35%	28%
2	14%	18%
3	7%	10%
4 – bedbound	2%	1
Unknown	n=1,011	n=8

NOTE: Column percentages may not add up to 100% due to rounding. For further details about the definitions of characteristics, please refer to the Audit's methodology supplement and glossary.

Supplementary Table 2. Care of people diagnosed with extrahepatic bile duct or ampullary tumours in England (2022-2023) and Wales (2023-2024)

	England	Wales
Time from referral to treatment		
Median time from referral to diagnosis (days, IQR)	10 (2 to 23); n=864	13 (2 to 54); 69
Median time from diagnosis to disease-targeted treatment (days, IWR)	52 (33 to 78); n=479	35 (16 to 51); 34
Median time from referral to disease-targeted treatment (days, IQR)	69 (48 to 107); n=479	69 (44 to 136); 34
% diagnosed within 21 days of referral	73%	58%
Received disease-targeted treatment		
Stage 1-3	67%	49%
Stage 4	36%	44%
Survival from diagnosis		
30-day	89%	
90-day	76%	
1-year	49%	
2-year	31%	NA